Business Model Breakdown
How Erasca Inc Makes Money
ERAS
Market Cap
$3.1B
The Short Version
Erasca is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for cancer, particularly by targeting the RAS/MAPK pathway. The company generates no revenue currently but aims to make money through the successful development and regulatory approval of its drug candidates, followed by direct sales or through licensing agreements with larger pharmaceutical companies. Its business model relies heavily on significant R&D investment, successful clinical trials, and eventually, market adoption of its proprietary cancer treatments.
Where the Revenue Comes From
Future product sales (anticipated, currently 0%)
Potential licensing agreements/royalties (anticipated, currently 0%)
Who buys: Future customers will primarily be oncology healthcare providers, hospitals, and ultimately, cancer patients with specific RAS/MAPK pathway mutations.
Why It Works (Competitive Advantages)
- ✔Targeting a historically challenging and high-value RAS/MAPK pathway in oncology.
- ✔Differentiated molecular glue approach (ERAS-0015) aiming for pan-RAS activity.
- ✔Experienced leadership team with deep oncology expertise.
Economic Moat: Narrow (Intangible Assets/IP (patents on novel small molecules and clinical data), Switching Costs (once a drug is adopted and effective for a patient))
What Our Analysis Says
DVR Score as of May 4, 2026
Erasca continues to pursue a high-potential oncology market (RAS/MAPK), backed by a solid cash position providing several years of runway and a pipeline of clinical assets. However, critical negative developments since the last analysis—including a patient death in a clinical trial that caused a ~55% stock drop, 'unfavorable' perception of ERAS-0015 pancreatic data, and a competitive allegation from Revolution Medicines—have significantly increased clinical and execution risks. While analyst sentiment remains broadly positive with notable upgrades, ongoing insider selling raises concerns. The resolved cash crunch is a strong positive, but these recent setbacks have clouded the 'best-in-class' narrative and created a much more precarious path to 10x growth, justifying a substantial downward score revision due to heightened risk and uncertainty.